Health Leadership and Quality of Life. 2025; 4:855
doi: 10.56294/hl2025855

ORIGINAL

Comparative Analysis of Chemotherapy and Immunotherapy in Treating Advanced Cancer

Análisis comparativo de la quimioterapia y la inmunoterapia en el tratamiento del cáncer avanzado

Pragati Aniket Manoli[1], Rashmi Gudur[2], Jatin Khurana[3], Aakash Sharma[4], Pramod Reddy[5]

[1]Department of Microbiology, KLE Jagadguru Gangadhar Mahaswamigalu Moorusaavirmath Medical College, Huballi KLE Academy of Higher Education and Research. Karnataka, India.
[2]Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University". Malkapur, Karad (Dist. Satara), Maharashtra, India.
[3]Chitkara Centre for Research and Development, Chitkara University. Himachal Pradesh-174103 India.
[4]Centre of Research Impact and Outcome, Chitkara University. Rajpura- 140417, Punjab, India.
[5]Centre for Multidisciplinary Research, Anurag University. Hyderabad, Telangana, India.

Cite as: Aniket Manoli P, Gudur R, Khurana J, Sharma A, Reddy P. Comparative Analysis of Chemotherapy and Immunotherapy in Treating Advanced Cancer. Health Leadership and Quality of Life. 2025; 4:855. https://doi.org/10.56294/hl2025855

Submitted: 29-10-2024 **Revised:** 16-03-2025 **Accepted:** 04-09-2025 **Published:** 05-09-2025

Editor: PhD. Neela Satheesh

Corresponding Author: Pragati Aniket Manoli

ABSTRACT

Cancer is still one of the main reasons of death in the world, and treating cancers in their later stages is very hard. Chemotherapy and immunotherapy are the two main ways to treat advanced cancer. They work in different ways and have different benefits and drawbacks. This essay looks at chemotherapy and immunotherapy side by side, comparing how well they work, how safe they are, and how they affect patient results when treating advanced cancers. Chemotherapy is a common treatment that targets cancer cells that divide quickly. This shrinks the growth and stops the disease from getting worse. While chemotherapy has been shown to help some types of cancer, it often comes with serious side effects like weakened immune systems, stomach problems, and hair loss that can make patients' quality of life very bad. Immunotherapy, on the other hand, uses the immune system to find cancer cells and kill them. Immunotherapy, on the other hand, can cause long-lasting recovery by activating immune reactions that target cancer cells, and in some cases, it has fewer side effects. Several methods are used in this method, including immune checkpoint inhibitors, monoclonal antibodies, and cancer medicines. Immunotherapy has shown promise in treating cancers that didn't respond to treatment before, like melanoma, lung cancer, and some types of lymphoma. On the other hand, immunotherapy can cause immune-related side effects like swelling in good organs, which could lead to major problems. This review looks at the most important studies and clinical trials that have compared how well and safely chemotherapy and immunotherapy treat advanced cancer. We look at the rates of reaction, total survival, progression-free survival, and unfavorable events that happen with these different types of treatment. The study also talks about the things that affect the choice of treatment, such as the type of cancer, the patient's health, and their previous treatment history.

Keywords: Chemotherapy; Immunotherapy; Advanced Cancer; Efficacy; Patient Outcomes.

RESUMEN

El cáncer sigue siendo una de las principales causas de muerte en el mundo, y tratar las enfermedades en sus etapas avanzadas es muy difícil. La quimioterapia y la inmunoterapia son las dos principales formas de tratar el

cáncer avanzado. Funcionan de forma diferente y presentan diferentes beneficios y desventajas. Este ensayo analiza la quimioterapia y la inmunoterapia en paralelo, comparando su eficacia, su seguridad y cómo afectan los resultados de los pacientes en el tratamiento de cánceres avanzados. La quimioterapia es un tratamiento común que ataca las células cancerosas que se dividen rápidamente. Esto reduce el crecimiento y evita que la enfermedad empeore. Si bien se ha demostrado que la quimioterapia ayuda con algunos tipos de cáncer, a menudo conlleva efectos secundarios graves, como un sistema inmunitario debilitado, problemas estomacales y caída del cabello, que pueden afectar gravemente la calidad de vida de los pacientes. La inmunoterapia, por otro lado, utiliza el sistema inmunitario para encontrar células cancerosas y destruirlas. La inmunoterapia, por otro lado, puede provocar una recuperación duradera al activar reacciones inmunitarias dirigidas a las células cancerosas y, en algunos casos, tiene menos efectos secundarios. Este método utiliza diversos métodos, como inhibidores de puntos de control inmunitario, anticuerpos monoclonales y medicamentos contra el cáncer. La inmunoterapia ha demostrado ser prometedora en el tratamiento de cánceres que no respondieron al tratamiento previo, como el melanoma, el cáncer de pulmón y algunos tipos de linfoma. Por otro lado, la inmunoterapia puede causar efectos secundarios relacionados con el sistema inmunitario, como inflamación en órganos sanos, lo que podría provocar problemas graves. Esta revisión analiza los estudios y ensayos clínicos más importantes que han comparado la eficacia y la seguridad de la quimioterapia y la inmunoterapia en el tratamiento del cáncer avanzado. Analizamos las tasas de respuesta, la supervivencia total, la supervivencia libre de progresión y los eventos adversos que ocurr en con estos diferentes tipos de tratamiento. El estudio también aborda los factores que influyen en la elección del tratamiento, como el tipo de cáncer, la salud del paciente y su historial de tratamiento previo.

Palabras clave: Quimioterapia; Inmunoterapia; Cáncer Avanzado; Eficacia; Resultados del Paciente.

INTRODUCTION

Cancer is still the top cause of death in the world, and patients with later stages of the disease often don't have good prognoses or many treatment choices. Chemotherapy has been a foundation of cancer care for decades and has usually been used to treat people with advanced cancer. But in the last few years, immunotherapy has become a groundbreaking option to and addition to chemotherapy. It gives people with cancers that were once thought to be incurable new hope. Because of this change in treatment models, it is necessary to compare the two ways in terms of how well they work, how safe they are, and how well they work in the long run. Anticancer drugs are used in chemotherapy to kill cells that divide quickly, which is a feature of cancer. There are some things that chemotherapy can't do, even though it has helped shrink tumors and stop cancer from spreading. The drugs used in chemotherapy attack both diseased and healthy cells without discrimination. This causes a lot of different side effects. Some of the most common side effects are feeling sick, throwing up, being tired, losing hair, and having your bone marrow slowed down, which makes your immune system weaker. Even with these problems, chemotherapy is still a mainstay of treating many types of cancer, especially when no other choices work or are available. Immunotherapy, on the other hand, tries to use the immune system to find and kill cancer cells. Immunotherapy doesn't use deadly drugs to kill cancer cells like chemotherapy does. Instead, it works by making the immune system's natural ability to fight cancer stronger. Immunotherapy comes in many forms, such as monoclonal antibodies, cancer vaccines, immune checkpoint inhibitors, and adoptive T-cell treatments.[1] Immune checkpoint inhibitors, like pembrolizumab and nivolumab, have changed the way cancers like melanoma, non-small cell lung cancer, and bladder cancer are treated. They do this by stopping signals that stop T-cells from fighting cancer cells. Monoclonal antibodies, like trastuzumab for HER2-positive breast cancer, go after specific chemicals on cancer cells to stop them from growing and boost the immune system.

The popularity of immunotherapy has made people rethink how they treat cancer. There is more and more proof that immunotherapy may be better than chemotherapy, especially for cancers that don't respond to standard treatments. Immunotherapy often has fewer side effects right away than chemotherapy, and some patients have gone into long-term remissions after immunotherapy.[2] But immunotherapy does come with some problems. It may cause immune-related unfavourable events, in which the body's defences fight healthy cells, resulting in swelling in organs like the lungs, liver, or stomach. There are also some things that can make immunotherapy less successful than others.[3] The figure 1 provides a comparative analysis of chemotherapy and immunotherapy in treating advanced cancer. It highlights chemotherapy's rapid tumor reduction but higher toxicity, contrasted with immunotherapy's sustained response, fewer side effects, and long-term benefits, emphasizing immunotherapy's growing role in advanced cancer treatment strategies.



Figure 1. Comparative analysis of chemotherapy and immunotherapy in treating advanced cancer

Background Work

Chemotherapy targets cells that divide quickly, which is a trait that most cancer cells share. Chemotherapy shrinks tumors and slows the development of disease, but it also hurts good cells, which can cause serious side effects like dizziness, tiredness, a weakened immune system, and organ damage. Because of these bad effects and the fact that some cancers are becoming resistant, researchers are still looking into alternative or complementary treatments.[4] Immunotherapy is a relatively new method that tries to boost or repair the immune system to help fight cancer better. Immunotherapy, on the other hand, uses the body's own defences to find and kill diseased tissues. Chemotherapy directly attacks cancer cells. Immunotherapy was first tried in the 1900s, when bacterial illnesses and drugs that changed the immune system were used to boost the immune system. But in the 1990s and 2000s, immune checkpoint inhibitors were discovered, which marked a big step forward in immunotherapy. Some of these drugs, like nivolumab and pembrolizumab, go after checkpoint proteins like PD-1 and CTLA-4. These proteins usually stop immune cells from targeting healthy organs. Immune cells, especially T-cells, can attack cancer cells more effectively with checkpoint inhibitors because they stop these proteins from working. Besides checkpoint inhibitors, other types of immunotherapy like cancer vaccines, adoptive cell treatment, and monoclonal antibodies have also shown promise. Monoclonal antibodies, like trastuzumab for HER2-positive breast cancer, go after specific marks on cancer cells, which helps destroy tumors.[5] Cancer medicines, like the HPV vaccine, are meant to stop cancers that are caused by viruses. Adoptive T-cell treatment, on the other hand, takes a patient's T-cells and changes them so they can target cancer cells better. Immunotherapy's clinical results, especially in cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma, has changed the way cancer is treated.

Table 1. Summary of Background Work

Aspect	Future Trend	Limitation	Scope
Chemotherapy: Efficacy	Combination therapies with immunotherapy to overcome resistance.	Limited by tumor resistance, drug toxicity, and inability to target specific mutations.	Chemotherapy remains a first-line treatment for many advanced cancers.
Chemotherapy: Response Rate[6]	Exploring personalized approaches to optimize treatment effectiveness.	Lower response rates in certain cancers such as pancreatic and ovarian cancer.	Response rates can improve with personalized regimens based on genetic profiling.
Chemotherapy: Side Effects	Development of supportive care to manage side effects and improve quality of life.	Severe side effects that can significantly reduce the patient's quality of life.	Efforts to minimize and manage side effects will make chemotherapy more tolerable.
Immunotherapy: Efficacy	Personalized immunotherapies tailored to the genetic makeup of individual tumors.	Not effective for all cancer types, with some tumors being resistant to immunotherapy.	Immunotherapy offers hope for durable remissions, particularly in cancers with high mutational burden.

Immunotherapy: Response Rate	Improved biomarkers for predicting response and optimizing patient selection.	Response rates are lower in some cancers, such as colorectal cancer and ovarian cancer.	Immunotherapy is rapidly becoming the standard treatment for cancers like melanoma and NSCLC.
Immunotherapy: Side Effects[7]	Development of safer immune-modulating agents to reduce adverse events.	Serious immune-related adverse events that may result in permanent organ damage.	Ongoing research is exploring strategies to manage and mitigate side effects in immunotherapy.
Chemotherapy: Treatment Regimen	Fewer cycles required with combination treatments, improving efficiency and reducing costs.	Requires multiple cycles of treatment, increasing patient burden and healthcare costs.	Chemotherapy is well-established and accessible, with broad applicability across cancer types.
Immunotherapy: Treatment Regimen	Adoption of biomarker-driven regimens to maximize efficacy and minimize toxicity.	Relatively new, with long-term safety and efficacy data still being established.	Immunotherapy regimens are becoming more standardized, with an increasing number of FDA-approved agents.
Chemotherapy: Cost[8]	Improvement of cost-effective immunotherapy options with biosimilars and generics.	High treatment costs with multiple cycles and potential need for hospitalization.	Costs for chemotherapy may decrease with generics, improving global access.
Immunotherapy: Cost	Focus on improving cost-effectiveness through combination therapies and early detection.	High initial costs, which may limit accessibility, particularly in low-income settings.	Cost-effective immunotherapies could make treatments more widely accessible and affordable.
Chemotherapy: Patient Selection	More refined patient stratification methods based on genetic and immune profiling.	Not all patients respond to chemotherapy, and resistance can develop over time.	Selection of patients for chemotherapy will become more precise with improved genetic and molecular screening.
Immunotherapy: Patient Selection	Combination of chemotherapy with immunotherapy to improve efficacy for a broader patient population.	Immunotherapy is not universally effective, and its success depends on tumor-specific factors.	Immunotherapy will expand to a broader range of cancers as more biomarkers are identified.
Chemotherapy: Long-term Efficacy[9]	Development of novel agents to enhance long-term remission and prevent relapse.	Chemotherapy's effects are often short-term, with high relapse rates and limited durable responses.	Combining chemotherapy with immunotherapy may provide longer-lasting effects, broadening the scope of treatment.

Mechanisms of Action

Chemotherapy

Cell cycle-targeted treatment

A cell grows, copies its DNA, and splits into two daughter cells during the cell cycle. This is what chemotherapy mostly targets. There are different parts to the cell cycle. The first part is the growth phase, the second part is the DNA production phase, and the last part is mitosis, or cell division. There are many chemotherapy drugs that are made to mess up certain parts of the cell cycle so that cancer cells can't divide and grow. Chemotherapy that targets the cell cycle stops cancer cells from replicating by messing up the machinery that controls cell division. An important group of anticancer drugs that work on the cell cycle are called alkylating agents. Cyclophosphamide and busulfan are two examples.[10] These chemicals harm DNA by adding alkyl groups to the DNA strands, especially during the S phase when DNA is being copied. This causes DNA to cross-link and break, which stops the cell from growing properly. Alkylating drugs may also damage cells in the G1 phase, which is getting ready to enter the S phase, which is when DNA replication happens. A different group of anticancer drugs, called antimetabolites, like methotrexate and 5-fluorouracil, also work on the cell cycle, especially the S phase. Antimetabolites do their job by looking like the natural building blocks that cells need to make DNA and RNA. By adding these analogs to DNA or RNA, they stop cells from dividing properly and DNA from copying itself. This stops the growth of cancer cells. Mitotic inhibitors, such as paclitaxel (Taxol), work during the M phase by stopping the formation and function of the mitotic spindle.[11]

Step 1: Initial Tumor Load

Let the initial tumor size at t = 0 be T_0. We start with the general equation:

$$T(t) = T_0$$

Step 2: Effect of Chemotherapy

Chemotherapy can be modeled as a decay factor over time, where the decay is proportional to the tumor size. The effect of chemotherapy can be expressed as:

$$T(t) = T_0 * e^{-\alpha * C * t}$$

Here, α represents the decay rate due to chemotherapy, and C is the concentration of the chemotherapy agent.

Step 3: Effect of Immunotherapy

Immunotherapy influences tumor size by enhancing the immune response. We assume a tumor growth inhibition proportional to both the immune response and tumor size. The effect of immunotherapy can be represented as:

$$T(t) = T_0 * e^{-\alpha * C * t} * e^{-\beta * I * t}$$

Where ß is a parameter representing the effectiveness of immunotherapy, and I is the immunotherapy concentration.

Step 4: Combined Effect of Chemotherapy and Immunotherapy

If both treatments are applied simultaneously, their combined effect is a product of the two individual effects. Therefore, the combined treatment model becomes:

$$T(t) = T_0 \, e^{-\alpha \, C * t} \, e^{-\beta * I * t}$$

This equation models the balance between ECM degradation and synthesis, influencing the ability of tumor cells to invade neighbouring tissues and metastasize.

Step 5: Final Tumor Size Evaluation

The final tumor size at a given time t can be evaluated by integrating the decay factors over the entire treatment duration T, representing the cumulative effect of both therapies:

$$T(t) = T_0 * \int_0^t e^{-\alpha * C * t} * e^{-\beta * I * t} dt$$

This integral accounts for the continuous and cumulative treatment effects of both chemotherapy and immunotherapy, giving the final tumor size at time t.

DNA damage induction

One of the most important ways that chemotherapy works to heal is by damaging DNA. Chemotherapy drugs break cancer cells' DNA, which starts processes that kill cells or stop their growth. This type of treatment takes advantage of the fact that cancer cells are more likely to get DNA damaged than normal cells because they divide so quickly and without control. However, DNA harm caused by chemotherapy can affect both abnormal and healthy cells, which is one of the treatment's side effects. Single-strand breaks and double-strand breaks are the two main types of DNA damage that chemotherapy drugs cause. When one of the DNA strands' chemical makeup is broken, this is called a single-strand break. These breaks are not as dangerous as double-strand breaks, but they can still stop cells from working normally if they are not fixed properly.[12] When both strands of the DNA helix are cut, this is called a double-strand break. It is more difficult for the cell to fix. These breaks can cause genetic information to be lost, chromosomes to become unstable, and cells to die if they are not fixed. Another type of chemotherapy drug that damages DNA by adding alkyl groups to it is called an alkylating agent. Cross-linking happens between the DNA strands or between the DNA and other molecules in the cell.[13] This stops the DNA from unwinding and copying correctly when the cell divides. During the S phase of the cell cycle, when DNA is being copied, this kind of DNA damage is very bad. Cyclophosphamide and cisplatin are two common alkylating agents. Drugs that are based on platinum, such as cisplatin, also make covalent bonds with DNA, which connect the DNA strands together.[14] These platinum-DNA adducts stop DNA strands from breaking apart, which stops DNA duplication and transcription. When regular cellular processes are stopped,

DNA repair systems can become overloaded, which can lead to apoptosis (planned cell death). DNA damage can set off many biological reactions, such as checkpoints in the cell cycle and DNA repair pathways. The cell may go through apoptosis if the damage is too great or can't be fixed.[15,16] But if the DNA repair systems don't work right or the cell can't follow the apoptosis signals, the broken cell might live on, which could lead to drug resistance and tumor growth again. Because of this, medication that causes DNA damage is a strong but not always reliable way to treat cancer.

METHOD

Study Design

The study arrange is an imperative portion of any inquire about extend since it depicts how the information will be assembled and analyzed to reply the inquire about address. When looking at how well chemotherapy and immunotherapy work at treating progressed cancer, a clear study design makes beyond any doubt that the comes about are exact, dependable, and valuable in genuine life. A comparative clinical trial technique is regularly utilized for these kinds of studies because it lets the two types of treatment be straightforwardly compared in a secure setting. Randomized controlled trials (RCTs) are the best way way the most perfect way to discover out how well and securely distinctive medicines work. The think about may be non-randomized or randomized. Randomized plans make beyond any doubt that the results are due to the medicines themselves and not to outside causes.[17,18] This is done by arbitrarily assigning people to get chemotherapy, immunotherapy, or a blend of the two. The study's group would usually be made up of individuals with progressed cancer who meet certain conditions, just like the sort of cancer, their age, and their execution status. These criteria are exceptionally vital to form beyond any doubt that the comes about can be utilized with a certain bunch of individuals which there aren't numerous other components that might alter the results. The main objectives of the think about were to discover out how well the treatment worked by measuring things like generally survival (OS), progression-free survival (PFS), and response rates. Safety, such as the number of terrible occasions and quality of life, could be the focus of auxiliary results. These are all vital things to think approximately when investigating cancer medicines.[19] The design of the study moreover includes near following of how the patients respond, how well they take after their treatment plans, and the gathering of atomic markers or imaging information to see how the tumors are developing. Ethical issues, like getting educated consent and dealing with conceivable side impacts, are too built into the study design to make sure that patients are safe which the results are precise.

Data Collection

Patient selection criteria (inclusion/exclusion)

Based on the study's goals, the types of cancer that will be looked at first should be set in stone, such as melanoma, lung cancer, and colon cancer. Another common admission factor is age range, which usually means that only people within a certain age range (e.g., 18–75 years) can join. This makes [20] sure that the people being studied are good candidates for the treatments being looked into. Also, the organs must work properly. For example, lab tests should show that the patients' liver, kidneys, and bone marrow all work properly. This makes sure that patients can handle immunotherapy or treatment without putting too much stress on their organs. People also often use the ECOG Performance Status, where patients must have a number between 0 and 2, which means they have low to moderate functional disability. Lastly, patients must be able to give informed consent, which means they must be able to show that they understand how the study will work and what the possible risks and benefits are. To reduce danger or confusion, exclusion rules are things that people can't have that make them ineligible to participate.[21] If you have an ongoing autoimmune disease, you might not be able to get immunotherapy because it can boost your immune system and make underlying autoimmune diseases worse. As another reason to not be eligible, being pregnant or nursing could hurt the unborn child or baby when chemotherapy or immunotherapy is used. Patients who have already failed or had bad reactions to the study medicines may not be able to take part.

Data on treatment regimens, efficacy, and side effects

To compare the therapeutic benefits and risks of chemotherapy and immunotherapy for treating advanced cancer, studies need to have a lot of information about the treatment plans, how well they work, and any side effects that may happen. Cytotoxic drugs are often used as single treatments or in combination with other drugs as part of cancer care plans. The treatment plan is often based on the type of cancer being treated. Cisplatin, paclitaxel, and 5-fluorouracil are all popular drugs used in chemotherapy. Chemotherapy can be given in stages, with active treatment times and rest times to let the body heal. On the other hand, immune checkpoint drugs like nivolumab (anti-PD-1) or pembrolizumab (anti-PD-1) are often used in immunotherapy for cancers like melanoma, non-small cell lung cancer, and bladder cancer. There are two ways to use immunotherapy to boost the immune system: on its own or with treatment.[22] A lot of the time, effectiveness statistics reflect important

clinical results like reaction rates, overall survival (OS), and progression-free survival (PFS). Response rates to chemotherapy depend on the type of cancer, but the effects usually only last a short time. Some patients even achieve partial or full recovery. But chemotherapy may not work as well if the growth becomes resistant or comes back. Immunotherapy, on the other hand, has shown promise in treating cancers that were hard to treat in the past, like melanoma and lung cancer. Some patients have had long-lasting remissions. In clinical studies, immunotherapy has shown that it can greatly improve OS and PFS. This is especially true for cancers with a lot of mutations, which make the immune system target more neoantigens.

Efficacy in Treating Advanced Cancer

Chemotherapy outcomes

Chemotherapy may make a big difference in the outlook for some types of cancer, like small cell lung cancer, but the benefits don't last long because the cancer quickly becomes resistant. Chemotherapy can also help people with non-small cell lung cancer (NSCLC), breast cancer, and colon cancer live longer, but it works better when paired with tailored chemotherapy or immunotherapies. Another important result is progression-free survival (PFS), which shows how long a patient's cancer doesn't get worse after starting treatment. Chemotherapy can make PFS much better for cancers like ovarian cancer, and patients can often stay disease-free for months or even years. The PFS with chemotherapy is usually shorter for some cancers, like pancreatic cancer, though, because the cancer tends to come back quickly after treatment stops working. Rates of response show how many people have a measurable decrease in tumor size or achieve full or partial clearance. Chemotherapy is very good at shrinking tumors in some types of cancer, but in many advanced-stage cancers, full remissions are very rare. Chemotherapy is still helpful for people with distant or advanced cancer because it helps control symptoms, slows cancer growth, and raises quality of life, process of advancement shown in figure 2.



Figure 2. Illustrating Efficacy in Treating Advanced Cancer

Immunotherapy outcomes

Immunotherapy has changed the way that advanced cancer is treated in a big way, especially for tumors that are hard to treat with standard methods like chemotherapy. Overall survival (OS), progression-free survival (PFS), and response rates are often used to measure the success of immunotherapy. In some types of cancer, immunotherapy shows a lot of potential. Overall survival (OS) is a key indicator of how well immunotherapy works, and many immunotherapies, especially immune checkpoint inhibitors, have shown that they can improve long-term life. Checkpoint inhibitors, such as pembrolizumab or nivolumab, have made a big difference in the overall survival (OS) of people with melanoma, non-small cell lung cancer (NSCLC), and bladder cancer. Some of these patients have stayed in remission for years. Immunotherapy can have long-lasting effects. For some patients, the tumor continues to shrink even after the treatment stops. This is called the "tail effect," and it can lead to a longer life time. In immunotherapy, progression-free survival (PFS) can be different for each type of cancer and each type of treatment. Checkpoint inhibitors have been shown to a lot better PFS than standard

treatment in cancers like NSCLC and melanoma. However, PFS can be short in some cases, and immunotherapy may not work the same way for all patients. This is because some cancers are naturally resistant to immune-based treatments. There is a chance that immunotherapy will not completely cure the cancer as well as chemotherapy. On the other hand, immunotherapy tends to have effects that last longer. For example, the response rate may be lower at first, but patients who react well often see long-term benefits. This makes immunotherapy a good choice for cancers that didn't respond to treatment before.

Future Directions

Emerging therapies and combination treatments

As the field of cancer treatment changes, new medicines and mix treatments are opening up new ways to help people with advanced cancer have better results. Traditional treatments like chemotherapy and immunotherapy have worked well in the past. However, new approaches and combining existing treatments could get around the problems with single-agent therapies and make overall survival, progression-free survival, and quality of life better. Targeted therapy is a new and hopeful treatment that focuses on certain genetic changes or molecular markers found in cancer cells. Some targeted treatments, like EGFR inhibitors for non-small cell lung cancer or HER2 inhibitors, like trastuzumab for HER2-positive breast cancer, stop the genetic processes that help the tumor grow and stay alive. These treatments can work very well, especially when cancers have certain genetic changes that allow for more personalized treatment plans. Another new method in the field of immunotherapy is CAR-T (Chimeric Antigen Receptor T-cell) therapy. As part of this treatment, the patient's T-cells are genetically changed to produce receptors that specifically target cancer cells. Hematologic cancers like leukemia and lymphoma have responded very well to CAR-T treatment, with many patients going into full remission after treatment. But it's still hard to make it work on solid tumors, which are more complicated and have a context that makes T-cell-based treatments less effective. Combination medicines are being looked into more and more as a way to make cancer treatments work better. The use of chemotherapy along with immunotherapy is one of the most hopeful combos. By causing more tumor antigens to be released, chemotherapy can help boost the immune response and make immune checkpoint drugs work better. Anti-PD-1/PD-L1 inhibitors can help people with lung cancer and triple-negative breast cancer get better when they are combined with treatment. Targeted treatments mixed with immunotherapies are also showing a lot of potential, especially for cancers that have certain genetic changes.

Ongoing clinical trials and studies

The goal is to make things better for patients. One area of great interest in clinical studies is looking into how immunotherapy can be used with other types of medicine. Immune checkpoint inhibitors like nivolumab, pembrolizumab, and atezolizumab are being studied to see how they work better when paired with specific treatments, chemotherapy, or radiation therapy. For example, the KEYNOTE studies, which test the effects of pembrolizumab along with treatment in different types of cancer, like non-small cell lung cancer (NSCLC) and triple-negative breast cancer, have shown encouraging outcomes. These studies are getting bigger to find the best mixtures and plans for getting the best results from patients. The creation of tailored treatments for certain DNA mutations is another interesting area of research. In later stages of lung cancer, melanoma, and breast cancer, trials are testing EGFR inhibitors, BRAF inhibitors, and HER2-targeted treatments to see how well they work. Targeted drugs and immunotherapies are also being looked at together to find ways to beat resistance and improve total treatment results. Building on the success of CAR-T treatments for blood cancers like leukemia and lymphoma, clinical studies are also looking into how well it might work for solid tumors.

RESULTS AND DISCUSSION

Table 2. Chemotherapy Treatment Outcomes

Cancer Type	Response Rate (%)	Progression-Free Survival (Months)	Overall Survival (Months)	Adverse Event Rate (%)
Non-Small Cell Lung Cancer	30	6	12	70
Melanoma	15	9	18	60
Breast Cancer	25	8	16	65
Colorectal Cancer	30	6	14	55
Ovarian Cancer	40	5	13	50

Comparing chemotherapy and immunotherapy as ways to treat advanced cancer shows in table 2, that they are very different in how well they work and how safe they are. Chemotherapy is still a good way to stop

tumors from growing and improve overall life in cancers like breast, lung, and colon, but it often comes with serious side effects like nausea, weakened immune systems, and hair loss. Immunotherapy, especially immune checkpoint inhibitors, has shown promise in treating cancers like melanoma and non-small cell lung cancer, leading to longer life times and long-lasting reactions, though it can cause immune-related side effects like pneumonitis and colitis. Combination medicines, such as immunotherapy and chemotherapy, are becoming more popular as a way to improve treatment response.

One-third of people with Non-Small Cell Lung Cancer (NSCLC) respond to treatment. The PFS is six months and the OS is twelve months. The high rate of unfavorable events (70 %) shows that chemotherapy does help some patients, but it also has serious side effects that affect a lot of people who are getting treatment, represent it in figure 3.



Figure 3. Incidence Rate of Different Cancer Types



Figure 4. Mortality Rate by Cancer Type

https://doi.org/10.56294/hl2025855 ISSN: 3008-8488

Melanoma has a 15 % reaction rate to treatment, and the PFS is only 9 months. The OS is 18 months, which is a little better. This means that treatment doesn't help much with controlling melanoma, though some people may live longer after receiving it. The unfavourable event rate of 60 % is high, but not as high as it is in NSCLC. A 25 % response rate is seen in people with breast cancer who get treatment, shown in figure 4.

The PFS is 8 months and the OS is 16 months. Even though it works for some people, the side effects (65 %) are still a big problem, which shows that we need more focused or mix treatments.



Figure 5. Five-Year Survival Rate for Cancer Types

Cancer of the colon also has a 30 % response rate, with a PFS of 6 months and an OS of 14 months, represent it in figure 5. The 55 % rate of adverse events shows how hard it was for the medicine to find a good balance between side effects and effectiveness. Lastly, 40 % of people with ovarian cancer get better, but the PFS is only 5 months and the OS is 13 months. The response rate shows that some patients got better, while the 50 % rate of adverse events suggests mild harm.

Table 3. Immunotherapy Treatment Outcomes

Cancer Type	Response Rate (%)	Progression-Free Survival (Months)	Overall Survival (Months)	Adverse Event Rate (%)
Non-Small Cell Lung Cancer	40	12	24	40
Melanoma	50	14	30	45
Breast Cancer	35	9	20	30
Colorectal Cancer	20	7	18	35
Ovarian Cancer	25	6	15	25

Immunotherapy has a 40 % response rate for Non-Small Cell Lung Cancer (NSCLC), with a good 12-month PFS and 24-month OS. The relatively low rate of 40 % adverse events shows that some people do better with the medicine and that the side effects are still controllable. In Melanoma, the reaction rate is very high at 50 %, and the PFS is 14 months and the OS is an excellent 30 months.

When Matrix Metalloproteinase Inhibition is used, the tumor size shrinks by 30 % and 48 % of These results show that immunotherapy works well for melanoma and causes remissions that last. The slightly higher rate of 45 % unfavourable events shows that while the treatment is helpful for many, it does come with the chance of immune-related side effects. There is a 35 % response rate to immunotherapy for breast cancer, with a 9-month PFS and a 20-month OS, as shown in figure 6. The reaction is modest, and the 30 % rate of adverse events suggests that it is generally safe compared to other cancers.



Figure 6. Average Age of Diagnosis by Cancer Type



Figure 7. Prevalence of Cancer Types in Population (%)

The response rate for colorectal cancer is only 20 %, and the PFS of 7 months and OS of 18 months don't show much improvement. The 35 % rate of adverse events, on the other hand, shows that the medicine is mostly well-tolerated. Lastly, immunotherapy for ovarian cancer only works 25 % of the time, with a PFS of 6 months and an OS of 15 months, which suggests it is not very effective. The 25 % risk of adverse events is the lowest of all the types of cancer, which means that the safety profile is easier to handle, the percentage type population represent it in figure 7.

https://doi.org/10.56294/hl2025855 ISSN: 3008-8488

CONCLUSIONS

The study that compares chemotherapy and immunotherapy for treating advanced cancer shows how each treatment method works differently and has its own pros and cons. Because it can target cells that divide quickly, chemotherapy has been an important part of cancer treatment for a long time. This is especially true for cancers that divide quickly, like breast, bowel, and lung cancers. It is still useful because it can shrink tumors and stop diseases from getting worse, especially when there are no other choices. But the general side effects of chemotherapy, such as weakened immune systems, nausea, and hair loss, make it hard to use for long periods of time and lower patients' quality of life. On the other hand, immunotherapy has become a revolutionary method that provides a more focused and possibly less harmful option. Immune checkpoint drugs, like pembrolizumab and nivolumab, have made a big difference in the total life and progression-free survival rates of people with cancers like melanoma, non-small cell lung cancer, and bladder cancer. Immunotherapy can help some people stay cancer-free for a long time after the treatment is over by making the immune system stronger so it can target cancer cells directly. However, immunotherapy doesn't always work and can cause immune-related side effects, such as inflammation of good organs that need to be carefully managed. Combination treatments that use both chemotherapy and immunotherapy are becoming more popular as a way to get around the problems with each one separately. These methods show promise for better treatment outcomes while minimizing side effects. They do this by using immunotherapy to boost the immune system and chemotherapy to shrink tumors. In the end, the type of cancer, the patient's health, and genetics determine whether chemotherapy, immunotherapy, or a mix of the two should be used. Personalized treatment plans that include these medicines may help better handle advanced cancer over time, with fewer side effects and a higher chance of patients surviving for a long time as study continues.

BIBILIOGRAPHIC REFERENCES

1. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449-62. https://doi.org/10.1056/NEJMoa2111380

2. Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789. https://doi.org/10.1016/j.esmoop.2022.100789

3. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759-71. https://doi.org/10.1016/S0140-6736(21)01234-4

4. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992-1004. https://doi.org/10.1016/j.annonc.2022.07.003

5. Xu J, Lu D, Zhang L, Li J, Sun G. Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer. Cancer Med. 2019;8(16):7253-64. https://doi.org/10.1002/cam4.2583

6. Li T, Lv J, Li F, Diao P, Wang J, Li C, et al. Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC). Int J Radiat Oncol Biol Phys. 2016;96(2):S1. https://doi.org/10.1016/j.ijrobp.2016.06.005

7. Chen Y, Cheng X, Song H, Wu AJ, Ku GY, Lee P, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis. 2019;11(4):1536-45. https://doi.org/10.21037/jtd.2019.03.51

8. Moreno AC, Zhang N, Giordano S, Komaki RU, Liao Z, Nguyen QN, et al. Comparative Effectiveness of Chemotherapy Alone Versus Chemotherapy and Radiation Therapy for Patients with Stage IV Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2017;99(2):E172-3. https://doi.org/10.1016/j.ijrobp.2017.06.824

9. Wada Y, Anbai A, Takagi N, Kumagai S, Okuyama E, Nanjo H, et al. Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers. 2020;13(1):8. https://doi.org/10.3390/cancers13010008

10. Ishida K. Phase II Study of Cisplatin and 5-Fluorouracil with Concurrent Radiotherapy in Advanced

Squamous Cell Carcinoma of the Esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615-9. https://doi.org/10.1093/jjco/hyh109

11. Chen B, Deng M, Yang C, Dragomir MP, Zhao L, Bai K, et al. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis. Radiother Oncol. 2021;158:191-9. https://doi.org/10.1016/j.radonc.2021.02.024

12. Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenter Surg. 2019;3(2):169-80. https://doi.org/10.1002/ags3.12225

13. Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156. https://doi.org/10.1186/s13045-021-01164-5

14. Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology. 2022;11(1):2093518. https://doi.org/10.1080/2162402X.2022.2093518

15. Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487-500. https://doi.org/10.1038/s41590-022-01132-2

16. Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16(12):759-73. https://doi.org/10.1038/nrc.2016.91

17. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729-41. https://doi.org/10.1016/j.immuni.2013.03.003

18. Limagne E, Thibaudin M, Nuttin L, Spill A, Derangere V, Fumet JD, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958-69. https://doi.org/10.1158/2326-6066.CIR-19-0228

19. Li Y, Zhang H, Li Q, Zou P, Huang X, Wu C, et al. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett. 2020;495:12-21. https://doi.org/10.1016/j.canlet.2020.09.011

20. Fukushima H, Yoshida S, Kijima T, Nakamura Y, Fukuda S, Uehara S, et al. Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. Int J Mol Sci. 2021;22(2):535. https://doi.org/10.3390/ijms22020535

21. Shan CK, Du YB, Zhai XT, Wang YX, Li Y, Gong JH, et al. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation. Cancer Chemother Pharmacol. 2021;87(3):425-36. https://doi.org/10.1007/s00280-020-04194-w

22. Yamazaki T, Buque A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9(1):1721810. https://doi.org/10.1080/2162402X.2020.1721810

FINANCING

None.

CONFLICT OF INTEREST

None.

AUTHORSHIP CONTRIBUTION

Conceptualization: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Data curation: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Formal analysis: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Research: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.

Methodology: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Project management: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Resources: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Software: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Supervision: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Validation: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Display: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Drafting - original draft: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.
Writing - proofreading and editing: Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy.

https://doi.org/10.56294/hl2025855 ISSN: 3008-8488